ORYZON Announces FDA Approval of IND for ETHERAL, a Phase IIa trial of the Epigenetic Drug Vafidemstat in Patients with Mild to Moderate Alzheimer’s disease
Recruitment is ongoing in Europe; The European and US Study will recruit a total of 150 patients MADRID, SPAIN and...